Ideal Cures Launches Two New Film Coating Products INSTACOAT QD and INSTACOAT T2F at the 2nd FDD Conclave

Food and Healthcare Press Releases Thursday July 5, 2018 14:29
MUMBAI, India--5 Jul--PRNewswire/InfoQuest

Ideal Cures, an Indian company headquartered in Mumbai, India, launched two new ready-to-use film coating products INSTACOAT QD and INSTACOAT T2F, at the 2nd Formulation and Drug Delivery Conclave (FDD), held on 15th-16th June 2018, at Hyderabad, India where more than 110 formulators of top India based pharma companies were present.

(Logo: )
INSTACOAT QD, quick disintegrating film coating product is revolutionary for pharmaceutical applications which provides fast disintegration of film within 3-30 seconds.

INSTACOAT T2F is a brilliant ready-to-use coating product by Ideal Cures that is completely free from Talc and TiO2. This product was developed because there have been many speculations, questions and concerns about talc and titanium dioxide as being carcinogenic. Hence, their use is discouraged in Europe and US.

Mr. Suresh Pareek, Managing Director of Ideal Cures Pvt. Ltd., who is also one of the inventors, said, "Ideal Cures is driven by its vision to provide the best solutions to the industry by continuously developing new and innovative products. We aimed to add another milestone to our mission of assisting the pharma industry with its need for better drug delivery systems and regulatory compliances with these two products."

About Ideal Cures:

Ideal Cures (IC) is amongst India's leading manufacturer and exporter of pharmaceutical excipients and ready-to-use coating systems for solid oral dosage forms. IC provides tailor-made solutions and products for the pharmaceutical and allied industries, through a network of customers and partners across more than 40 countries around the world. It is the first film coating company to have all its cGMP compliant manufacturing plants EXCiPACT(TM) certified. IC's latest manufacturing facility in Sikkim will be certified in due course. An ISO 9001:2015 certified company with a US DMF for all its manufacturing facilities; IC is one of the most innovative film-coating companies.

For a comprehensive, time-saving tablet coating experience, Talk to Us!
Join us on   LinkedIn for quick updates on our new product launches and upcoming events!
Media Contact:
Saryu Pareek Gupta
Vice President - Corporate Communications
Ideal Cures Pvt. Ltd., Mumbai, India
Web -
India HO and R&D centre
A-223 to 229, Virwani Industrial estate
Off western express highway
Goregaon (East), Mumbai - 4000063
Source: Ideal Cures Private Limited

Latest Press Release

Takeda, Microsoft and EURORDIS release report with action plan to help rare disease community shorten the diagnostic odyssey

- Global Commission's recommendations focus on three solution pathways that leverage technology to address key elements of the rare disease diagnostic odyssey - Rare diseases remain undiagnosed as patients struggle to navigate complex health systems to...

Pivotal Phase III Data for BAVENCIO(R) (avelumab) Plus INLYTA(R) (axitinib) in Advanced Renal Cell Carcinoma Published in the New England Journal of Medicine

- JAVELIN Renal 101 shows significant improvement in progression-free survival with a hazard ratio of 0.69 in patients regardless of PD-L1 expression - US FDA has granted Priority Review to BAVENCIO plus INLYTA for patients with advanced renal cell...

ISABS เตรียมจัดการประชุมว่าด้วยการแพทย์ส่วนบุคคลที่โครเอเชีย พร้อมเชิญเจ้าของรางวัลโนเบลร่วมบรรยาย

International Society for Applied Biological Sciences (ISABS) ร่วมกับ Mayo Clinic และ St. Catherine Hospital เตรียมจัดการประชุม "ISABS Conference on Forensic and Anthropologic Genetics and Mayo Clinic Lectures in Individualized Medicine" ครั้งที่ 11...

ISABS: Personalized Medicine Conference With Nobel Laureates to Be Held in Split, Croatia

International Society for Applied Biological Sciences (ISABS), Mayo Clinic and St. Catherine Hospital are organizing "11th ISABS Conference on Forensic and Anthropologic Genetics and Mayo Clinic Lectures in Individualized Medicine"(

Beijing Intellectual Property Court Confirms Judgment Against Wuxi Hisky Medical for Patent Infringement of Technology Used for Echosens# FibroScan(R), Imposes Damages Orders Halt to Manufacturing and Sales

Echosens, an innovative high-technology company offering the FibroScan family of products dedicated to assessment of chronic liver disease, today announces that the Beijing Intellectual Property Court has confirmed judgment against Wuxi Hisky Medical,...

Related Topics